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Abstract
Background:  Deregulated cell cycle progression and loss of proliferation control are key
properties of malignant cells. In previous studies, an interactive transcript abundance index (ITAI)
comprising three cell cycle control genes, [MYC × E2F1]/p21 accurately distinguished normal from
malignant bronchial epithelial cells (BEC), using a cut-off threshold of 7,000. This cut-off is
represented by a line with a slope of 7,000 on a bivariate plot of p21 versus [MYC × E2F1], with
malignant BEC above the line and normal BEC below the line. This study was an effort to better
quantify, at the transcript abundance level, the difference between normal and malignant BEC. The
hypothesis was tested that experimental elevation of p21 in a malignant BEC line would decrease
the value of the [MYC × E2F1]/p21 ITAI to a level below this line, resulting in loss of immortality
and limited cell population doubling capacity. In order to test the hypothesis, a p21 expression
vector was transfected into the A549 human bronchogenic carcinoma cell line, which has low
constitutive p21 TA expression relative to normal BEC.
Results: Following transfection of p21, four A549/p21 clones with stable two-fold up-regulated
p21 expression were isolated and expanded. For each clone, the increase in p21 transcript
abundance (TA) was associated with increased total p21 protein level, more than 5-fold reduction
in E2F1 TA, and 10-fold reduction in the [MYC × E2F1]/p21 ITAI to a value below the cut-off
threshold. These changes in regulation of cell cycle control genes were associated with restoration
of cell proliferation control. Specifically, each transfectant was capable of only 15 population
doublings compared with unlimited population doublings for parental A549. This change was
associated with an approximate 2-fold increase in population doubling time to 38.4 hours (from
22.3 hrs), resumption of contact-inhibition, and reduced dividing cell fraction as measured by flow
cytometric DNA analysis.
Conclusion: These results, likely due to increased p21-mediated down-regulation of E2F1 TA at
the G1/S phase transition, are consistent with our hypothesis. Specifically, they provide
experimental confirmation that a line with slope of 7,000 on the p21 versus [MYC × E2F1] bivariate
plot quantifies the difference between normal and malignant BEC at the level of transcript
abundance.
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Background
Bronchogenic carcinoma (BC) is the leading cause of can-
cer-related death in the United States and most industrial-
ized nations [1]. It is reasonable to expect that improved
mechanistic understanding of BC will lead to reduced
death rate through more effective prevention and treat-
ment regimens.
In an effort to identify biomarkers that diagnose BC with
more accuracy than cytomorphologic criteria, this labora-
tory developed and has employed a highly quantitative,
quality controlled RT-PCR method, Standardized RT
(StaRT)-PCR [2-4]. With StaRT-PCR, data from all experi-
ments may be directly compared in the same database.
This leads to synergistically increasing value of data over
time as data accumulate. Also, because the data are all
numerical and standardized, they are easily combined
into interactive transcript abundance indices (ITAI). ITAI
typically are more closely associated with the phenotype
of interest and are more likely to yield clinically useful
biomarkers than values for individual genes, either alone
or in multivariate analysis [5-7]. Initially, StaRT-PCR was
used to measure the transcript abundance (TA) values of
fifteen cell proliferation control genes (including MYC,
E2F1, p21, RB1, PCNA, cyclin D2, cyclin D3, and p53) [6].
Although TA values for any single gene did not accurately
distinguish normal from malignant human bronchial epi-
thelial cells (BEC), an ITAI in the form of [MYC × E2F1]/
p21 (using a cut-off value of 7,000) was accurate [2,6,8].
In previous studies of the association between the [MYC ×
E2F1]/p21 ITAI and malignancy, it was observed that
there is substantial variation in transcriptional regulation
of p21 among BC tissues [9]. In some BC samples, p21
expression is low relative to normal BEC, and in others it
is markedly elevated. For example, in some BC there is
decreased p53 function mediated by a mutation in the
p53 regulatory pathway (e.g. p14ARF deletion in A549)
[10], resulting in inappropriately low p21 expression and
an ITAI above 7,000. In this context, even relatively low
levels of MYC and E2F1 are sufficient to cause loss of pro-
liferation control. However, even in BC tissues with high
p21, the [MYC × E2F1]/p21 ITAI value is nearly always
above 7,000. This suggests that E2F1 and/or MYC are
increased to high enough levels and compensatory path-
ways, represented by p21 TA level, are inadequate to
ensure cell proliferation control.
The p21WAF1/CIP1 gene is a key regulator of cell cycling [9].
Up-regulation of p21WAF1/CIP1, which occurs mainly at the
transcriptional level [11,12], is mediated primarily by the
tumor suppressor p53 after genotoxic stress [13]. In turn,
p21 protein interacts with cyclin-cdk complexes [14-16],
associates with pRb protein [17], PCNA [18-20], GADD45
[21,22], cooperates with 14-3-3 [23], and/or modulates
the activities of DNA polymerase δ [24]. These molecular
changes are associated with growth arrest [13], senes-
cence, terminal differentiation, apoptosis, and contact
inhibition [11]. These and other changes mediated by
either p53-dependent [13] and/or p53-independent
means (i.e. Sp1/Sp3, Smads, Ap2, STAT, and BRCA1
(reviewed in [25])) contribute to G1 [26] and G2 check-
point control [27] and regulation of the cell cycle. Experi-
mental up-regulation through ectopic p21 expression [22-
26] or stimulation of endogenous p21 transcription [28-
30] results in controlled cell proliferation.
The purpose of these studies was to better quantify, as
measured by TA values, the relationship among key genes
associated with cell proliferation control. Based on previ-
ous studies, a cut-off threshold of 7,000 for the [MYC ×
E2F1]/p21 ITAI accurately distinguishes normal from
malignant lung samples. The hypothesis was tested that
this empirically derived cut-off is mechanistically deter-
mined and is a mathematical representation of the differ-
ence between normal BEC and malignant BEC. First, the
malignancy ITAI genes MYC, E2F1, and p21 were meas-
ured in an additional set of primary normal and malig-
nant lung samples to more firmly establish the threshold
separating them. Then, experimental studies were con-
ducted on the human BC line, A549. This line was chosen
because it has down-regulated p21 expression, in part due
to p14ARF deletions [10], resulting in an ITAI above the
cut-off threshold of 7,000. If the hypothesis was correct,
stable exogenous expression of p21 in A549 would
decrease the ITAI ratio to a level that is below this cut-off.
Four A549 clones (1, 29, 30, and 32) that express
increased constitutive levels of endogenous and exoge-
nous p21 were established. The mathematical relation-
ship among TA values of the genes comprising the ITAI
was measured and the effects on cell cycling and prolifer-
ation control were examined.
Results
Determination of the ITAI cut-off value that separates 
normal from malignant BEC
Previously, we reported that a cut-off threshold of 7,000
for the [MYC × E2F1]/p21 ITAI accurately distinguishes
normal from malignant BEC [8]. An additional 65 normal
and 31 malignant samples were assessed for this study
and the results, combined with data from previous stud-
ies, are presented in Figure 1 and in Additional File 1. In
these studies, sensitivity and specificity are greater than
90% for distinguishing normal from malignant BEC using
a value of 7,000 for the ITAI. Among primary samples,
there are numerous factors not present in cell lines that
may contribute to false negatives and/or false positives.
False positives (high index value in morphologically non-
malignant samples) may be due to poor sample quality
and RNA degradation or incorrect morphological diagno-Molecular Cancer 2006, 5:1 http://www.molecular-cancer.com/content/5/1/1
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sis. False negatives (low index value in morphologically
malignant samples) may be due to small fraction of tumor
cells in the biopsy sample, or incorrect morphological
diagnosis.
Describing the ITAI threshold as a linear equation derived 
from cell cycle gene TA values
Because the [MYC × E2F1]/p21 ITAI is a ratio between two
values, the cut-off is best represented as a line on a bivari-
ate plot. On a plot of all normal or malignant samples the
ITAI threshold is represented as a line with a slope of
7,000 that passes through the origin (Figure 2). Thus,
some malignant BEC have a very high p21 level and are
above the cut-off only because they also have a very high
[MYC × E2F1] value (e.g. H446), while others have a low
p21 level and a relatively low [MYC × E2F1] level is suffi-
cient to place them above the cut-off. In this way, the cut-
off separates nearly all malignant from all normal sam-
ples. A549 is a good example of this phenomenon. The
p21 TA level was higher than many normal BEC samples
and the [MYC × E2F1] TA level was lower than some nor-
mal BEC samples. Yet, the p21 to [MYC × E2F1] ratio was
above the ITAI cut-off.
Expression of index genes and the ITAI in parental A549 
and A549/p21 clones
Stable low-level expression of p21 RNA and protein were
observed during screening of A549 clones 1, 29, 30, and
32, and these clones were used in all subsequent studies.
Doxycycline did not increase expression of p21 in these
lines. Total p21 TA value (combined exogenous p21 plus
endogenous p21 expression-see Methods) was signifi-
cantly (p < 0.05) increased two-fold in each of the A549/
p21 clones compared to the parental A549 (Figure 3). The
Histogram analysis of the [MYC × E2F1]/p21 ITAI Figure 1
Histogram analysis of the [MYC × E2F1]/p21 ITAI. Each data set comprises either cultured or primary normal bronchial 
epithelial cell (NBEC) or cultured or primary malignant bronchial epithelial cell (MBEC) samples assessed for the ITAI. The ITAI 
cut-off is indicated by the horizontal line at 7,000 molecules. Parental A549 is indicated.
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increase in total p21 at the RNA level was associated with
a corresponding increase in total p21 protein measured by
Western blot analysis (Figure 4a). StaRT-PCR confirmed
the expression of exogenous p21 TA in the A549/p21
clones (data not shown), and exogenous p21 protein
expression was confirmed by Western blot analysis of the
Hexa-His-tagged p21 (Figure 4b).
Expression of Hexa-His-tagged p21 was observed in each
clone (lanes 2–5) but not in the parental A549 (lane 1). A
higher molecular weight protein(s) was observed in the
lysates from the clones suggesting a non-specific antigen/
antibody interaction. This increase in total p21 expression
was associated with a greater than 5-fold significant (p <
0.05) decrease in E2F1 TA in each clone (Figure 3). Fur-
ther, the 2-fold increase in p21 TA and 5-fold decrease in
E2F1 TA resulted in a greater than 10-fold significant (p <
0.05) decrease in the ITAI in each of the A549/p21 clones
relative to parental A549 (Figure 5a), to levels below the
cut-off threshold of 7,000 (Figure 2 and 5b). With the
exception of A459/p21 clone 1, there was no significant
statistical difference in MYC TA among the remaining sta-
ble transfectants and parental A549 (Figure 3). Further,
among the A549/p21 clones, variation in expression of
MYC, E2F1, and p21 and the resultant ITAI were insignif-
icant.
Growth kinetics of A549 and A549/p21 clones
Decreasing the ITAI to a level below 7,000 was associated
with increased doubling time indicative of p21 effects on
A549 proliferation kinetics. There was a nearly 2-fold
increase in doubling time in each of the clones from 22.3
hrs for parental A549 to an average of 38.4 hrs in the four
clones, in either antibiotic selection medium or antibi-
otic-free medium (Table 1). The rate of proliferation for
the A549/p21 clones significantly (p < 0.05) decreased (0
hrs to 72 hrs) and dramatically decreased after 72 hrs with
no significant change in number of cells between 72 and
96 hrs, and viability decreased at high saturation density
(80% confluency) (Figure 6). Despite variable seeding
densities (1 × 105, 5 × 105, and 1 × 106 cells) of the A549/
p21 clonal populations, the cells ceased to proliferate and
viability decreased at 80% confluency further suggesting
p21-mediated contact inhibition at high saturation densi-
ties (data not shown). While the differences in prolifera-
tion rates were significant between parental A549 and the
A549/p21 clones, there were no significant differences
among any of the individual clones. Each of the A549/p21
clones was capable of approximately 15 total doubling
times based on the estimated number of cells in the estab-
lished initial foci (≈1 × 102 cells) compared to the esti-
mated number of cells in the seventh passage, which was
the last passage that they were capable of (data not
shown). These passage limitations are similar to the pas-
sage limitations of cultured normal BEC [28].
Flow cytometric DNA analysis for A549 and A549/p21 
clones
Decreasing the ITAI across the cut-off level between nor-
mal and malignant BEC was associated with p21-medi-
ated cell-cycle arrest and/or delayed S-phase entry
indicative of restored proliferation control. For the paren-
tal A549, 53.2% and 36.9% of cells were in G1 and S-
phases respectively (Figure 7a). In contrast, in the A549/
p21 clones, the G1 fractions were increased to an average
of 80.7% (73.7%, 85.4%, 76.3%, and 87.3% in each
respective clone) and the S-phase fractions were decreased
to an average of 15.4% (21.4%, 10.6%, 19.1%, and 10.3%
in each respective clone (Figure 7b–e)
Discussion
Diagnostic tests, including those based on molecular diag-
nostic biomarkers, require establishment of a cut-off value
to separate one clinically important phenotype from
another. Cut-off values for multiple variables may then be
combined through multivariate analysis to derive a diag-
nostic test with better accuracy than any of the individual
cut-off values [5-7]. When attempting to approximate a
complex phenotype through TA measurement, a signifi-
cant limitation of multi-variate analysis is that it does not
cause the individual variables to mathematically interact.
It is not possible to deduce how the TA level of each gene
scales with respect to a particular phenotype, nor how
multiple genes interact at the TA level to give rise to a phe-
notype. It is likely that the scaling varies from one gene to
another, and that interactions among the genes may
involve both linear and non-linear functions. This is one
reason that combination of TA values into ITAI leads to
development of biomarkers with improved accuracy and
ITAI biomarkers for clinical diagnostics have now been
described [5-7]. It is important to recognize that the cut-
off values for these ITAI represent lines on bivariate plots.
One implication is that there is no prior reason that the
best cut-off line will pass through the origin, as it does for
the [MYC × E2F1]/p21.
A bivariate plot of p21 versus [MYC × E2F1] enables quan-
titative experimental investigation of the relationship
between MYC, E2F1, and p21 individual transcript abun-
dance values and the ITAI cut-off value that distinguishes
normal from malignant BEC. For example, a malignant
BEC line with a low [MYC × E2F1] value relative to most
BC samples may be malignant if the p21 value also is rel-
atively low. This was the case with parental A549.
Although the A549 [MYC × E2F1] value is lower than in
most malignant tissues (Figure 2), the ITAI value is above
the cut-off threshold because the p21 level is low relative
to the [MYC × E2F1] value. In contrast, a sample with a
high p21 may be malignant if the [MYC × E2F1] value is
sufficiently high, as was observed, for example, in theMolecular Cancer 2006, 5:1 http://www.molecular-cancer.com/content/5/1/1
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bronchogenic carcinoma cell line H446 (Figure 2, and
[9]).
From these empirical observations, we selected the A549
cell line for subsequent experiments because its ITAI value
was in close proximity to the cut-off threshold, and it was
anticipated that even a relatively small increase in p21 TA
value would be associated with restoration of cell prolifer-
ation control. Because it was anticipated that high consti-
tutive expression of p21 would inhibit cell cycling to the
extent that it would not be possible to isolate transfected
clones, the goal was to obtain stable p21 transfectants that
were under control of a tetracycline inducible promoter.
Because the tetracycline repressor was not functional in
the transfectants, exogenous p21 expression was not
repressed in the absence of tetracycline, but was constitu-
tively active. Thus, two selection processes were operative.
On the one hand, there was antibiotic selection for clones
with stable integration of the transfected p21 expression
vector. On the other hand, survival and clonal expansion
also was dependent on a p21 expression level low enough
to allow cell cycling. Therefore, while expression and
growth kinetics varied significantly between A549 and the
stable, constitutively expressing p21 A549-derived clones,
the observed lack of clonal variation (insignificant differ-
ences in expression and growth kinetics among the A549/
p21 clones) supports these two selection processes. Each
successfully isolated A549/p21 clone had total p21
expression that was elevated relative to parental A549, but
was low enough to allow 15 doublings, which was suffi-
cient for the studies reported here.
The absence of inducible clones could have been due to a
number of factors, including promoter degradation, dele-
terious vector integration, and/or sub-optimal selection
conditions affecting either the tetracycline repressor vec-
tor or the p21 expression vector.
In each A549/p21 clone we observed 1) a two-fold
increase in p21, accompanied by 2) a 5-fold decrease in
E2F1 TA and 3) that a 10-fold reduction in the ITAI was
sufficient for each A549/p21 clone to cross the cut-off
threshold of 7,000. This was associated with marked
reduction in cell cycle progression and cell proliferation in
the A549/p21 clones.
p21 exerts its inhibitory function in either late G1 or late
G2 of the cell cycle [26,27]. Consistent with this, our
results demonstrate that in the A549/p21 clones, cell cycle
arrest and delayed progression through the cell cycle was
mediated at late G1 based on the average increase in the
fraction of cells in G1-phase and the average decrease in S-
phase of the clones relative to the parental cell line. More-
over, because E2F1 expression is important for S-phase
progression (reviewed in [29]) and is up-regulated in
A549 due, in part, to p14ARF deletions, which normally
serves to suppress E2F1 both directly [30] and through
inhibition of MDM2 leading to activation of p53 [31], it
is reasonable to conclude that down-regulation of E2F1
mediated by up-regulated p21 expression contributed to
growth inhibition at late G1. Because RB1 (retinoblast-
oma) is intact in A549 and is a substrate of cyclin-cdk
function, inhibition of these regulatory complexes and/or
pRb directly [17] by p21 may have contributed to
decreased or inhibited pRb phosphorylation. This, in
turn, would be associated with diminished E2F1 dissocia-
tion, decreased E2F1 auto-up-regulation [32,33] and
attenuated progression through the cell cycle. However,
another possibility has been reported, where p21 has been
shown to directly associate with E2F [34].
Bivariate analysis of p21 and [MYC × E2F1] Figure 2
Bivariate analysis of p21 and [MYC × E2F1]. The X-
axis represents p21 TA while the Y-axis represents the 
expression product of [MYC × E2F1]. The cut-off value is 
indicated by a line with the slope of 7,000. Open symbols 
represent non-malignant (normal) BEC samples, while filled-
in symbols represent malignant BEC samples. All cultured 
BEC samples are indicated as squares. Primary normal BEC 
samples are indicated as circles, and primary normal paren-
chyma samples are indicated as diamonds. Primary malignant 
BEC samples are indicated as triangles. H446, A549 and 
A549/p21 clones are indicated.
1.00E+05
1.00E+06
1.00E+07
1.00E+08
1.00E+09
1.00E+10
1.00E+11
1.00E+12
1.00E+02 1.00E+03 1.00E+04 1.00E+05 1.00E+06
p21
[
M
Y
C
 
x
 
E
2
F
1
]
Y=(7000)X
A549
A549/p21s
H446Molecular Cancer 2006, 5:1 http://www.molecular-cancer.com/content/5/1/1
Page 6 of 13
(page number not for citation purposes)
MYC TA level was not decreased considerably in the
A549/p21 stable clones compared to the parental A549 in
the context of a five-fold decrease in E2F1 TA level. This is
in contrast to reports that in some contexts E2F1 is a tran-
scription factor for MYC [35] and that reciprocal regula-
tion occurs between MYC and p21 [36]. One possible
explanation for this is that one or more transcription fac-
tors other than E2F1 contribute to MYC regulation. It is
notable that a decrease in the ITAI to below the cut-off
level, delay of cell cycle progression and re-establishment
of proliferation control may be accomplished without sig-
nificant alteration in MYC TA level, provided that suffi-
cient alteration of p21 and E2F1 occur. Further, while
MYC is a proven oncogene and increased expression of
MYC causes oncogenic transformation in lung epithelial
Combined endogenous plus exogenous p21 expression and E2F1 and MYC expression for A549, A549/p21 clone 1, 29, 30, and  32 Figure 3
Combined endogenous plus exogenous p21 expression and E2F1 and MYC expression for A549, A549/p21 
clone 1, 29, 30, and 32. Total p21 TA levels (e + e: endogenous plus exogenous), E2F1 TA levels, and MYC TA levels are 
indicated. Each column and error bar represents mean and standard deviation of at least triplicate measurements.
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Table 1: Doubling time for A549 and A549/p21 clones.
Doubling time (hours)1
Sample w/ w/o
antibiotic2 antibiotic
A549 (parental) NA3 22.3
A549/p21 clone 1 39.3 38.5
clone 29 39.5 38.2
clone 30 39.3 39.3
clone 32 38.2 37.7
1) Doubling time was calculated by plotting the graph of cell count vs. 
time using the third degree polynomial. 2) Populations grown in 450 
µg/mL G418 (minimum lethal dose 100). 3) No growth of parental 
A549 in medium containing selectable antibiotic; all populations 
grown in RPMI and 10% FBS.Molecular Cancer 2006, 5:1 http://www.molecular-cancer.com/content/5/1/1
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cells (reviewed in [37]), these studies indicate that regain-
ing MYC regulation is sufficient, but not necessary to re-
establish cell cycle control in malignant cells. Others have
made observations in other models consistent with those
described here. For example, Boxer et al. observed that
mammary adenocarcinomas that showed down-regula-
tion of MYC retained their malignant properties and that
transformation of residual neoplastic cells was independ-
ent of MYC expression [38].
Normal BEC exhibit contact inhibition in culture at par-
ticular cell densities and cellular senescence (irreversible
growth arrest) [28]. Cessation of proliferation and loss of
viability in the A549/p21 clones after 72 hrs of continu-
ous high saturation density likely was mediated by up-reg-
ulation of p21. This response has been observed in
melanoma cells over-expressing p21 [39]. This p21 effect
may be mediated in part through the up-regulation of H-
cadherins [40] and/or T-cadherins independent of p53
[41]. Also, cell-to-cell contacts initiate prolonged nuclear
localization of p21 that leads to growth arrest and apop-
tosis [39] and this effect may have been accentuated due
to exogenous p21 up-regulation. Normal alveolar epithe-
lial cells or A549 cells, exposed to sub-lethal doses of cig-
arette smoke, over-express p21 and undergo cellular
senescence both in vitro and in vivo [42]. The cytokine,
TGF-β, has been demonstrated to up-regulate p21 [43],
and A549 cells treated with TGF-β over a long period were
forced to undergo senescence and senescent A549 cells
were not tumorigenic in nude mice [44]. Increased p21
expression has been associated with G1 growth arrest and
senescence in hepatoma cells treated with ninjurin 1, a
novel adhesion molecule that promotes regeneration in
nervous tissue but senescence in liver tissue [45].
Conclusion
In conclusion, characterization of the role of p21 in regu-
lating cell proliferation and better quantification of the
balance among cell proliferation control genes, as meas-
ured by TA values, was achieved through a moderate up-
regulation of p21 in the A549 cell line. This allowed
experimental quantitative confirmation that a cut-off level
of 7,000 for the [MYC × E2F1]/p21 ITAI distinguishes
between malignant and non-malignant phenotypes. This
will guide development of more accurate diagnostic tests
and more effective gene-targeted therapeutics.
Methods
Cell lines and culture conditions
The parental A549 cell line was cultured in RPMI 1640
with 10% fetal bovine serum (Clonetics, San Diego, CA).
The A549/p21 clones 1, 29, 30, and 32 were continuously
maintained in RPMI and 10% Tet-system approved FBS
(Clontech, Palo Alto, CA) with 450 µg/mL Geneticin
(G418 sulfate) (Invitrogen, Inc., Carlsbad, CA) unless oth-
erwise noted.
Culture conditions for normal and malignant BEC were
described previously [3]. Normal and malignant BEC pro-
liferate optimally under different conditions [46]. The
medium that is optimal for malignant BEC, RPMI with
10% fetal bovine serum (Clonetics, San Diego, CA),
induces terminal squamous differentiation in normal
BEC [28]. Conversely, malignant BEC do not divide in
serum-free medium that is optimal for proliferation of
Western blot analysis of combined exogenous and endog- enous p21 protein and exogenous p21 protein expression  from A549, A549/p21 clone 1, 29, 30, and 32 cell lysates Figure 4
Western blot analysis of combined exogenous and 
endogenous p21 protein and exogenous p21 protein 
expression from A549, A549/p21 clone 1, 29, 30, and 
32 cell lysates. A) Total p21 protein was analyzed in paren-
tal A549 or A549/p21 clones, which express stable low-level 
exogenous p21. Twenty µg of lysate were blotted on a PVDF 
membrane and incubated with anti-Waf1 (p21) (Ab-1) pri-
mary monoclonal antibody. B) Exogenous p21 protein was 
confirmed in the A549/p21 clones. Twenty µg of lysate were 
blotted on a PVDF membrane and incubated with anti-His 
Tag monoclonal antibody recognizing the Hexa-Histidine 
fusion tag of p21 transactivated from the expression vector 
contained in the stable A549/p21 clones. The asterisk indi-
cates the non-specific antigen/antibody interaction.
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normal BEC. Thus, the 13 malignant BEC lines were cul-
tured in RPMI with 10% FBS and normal BEC from eight
individuals (Clontech lot numbers: 10525, 17378,
6F0333, 6F0450, 17684, 17714, 6F0395, and 7F0075)
were cultured in serum-free BEGM growth medium
(Clonetics, San Diego, CA). In order to directly compare
carcinoma cell lines to normal BEC under the same cul-
ture conditions, five of these normal BEC cell popula-
tions, 10525, 17378, 6F0333, 6F0450, and 17684 were
incubated for 24 hours in RPMI with 10% FBS directly
prior to assessment (Additional File 1).
Primary tissue samples
Sixty-five primary normal BEC samples and thirty-one pri-
mary bronchogenic carcinoma samples (Additional File
1) were obtained under IRB approved protocols as
described previously [6,8].
Construction and cloning of p21 expression vector
The GeneStorm hORF Expression Vector (pcDNA3.1/GS),
containing the complete cDNA sequence of the cyclin-
dependent kinase inhibitor 1A (p21, Cip1) (Accession
L25610) was obtained from Invitrogen, Inc., (Carlsbad,
CA); The Gateway cloning system (Invitrogen, Inc.,
Carlsbad, CA) was used to create the p21 expression vec-
tor. Primers were designed to amplify the full-length p21
cDNA insert (Forward primer 5' end flanked by CACC,
5'CACCATGTCAGAACCGGCTGG3'  and reverse primer
5'TCAATGGTGATGGTGATGAT3') were suitable for direc-
tional Topoisomerase (TOPO) cloning (Invitrogen, Inc.,
Carlsbad, CA) into pENTR/D-TOPO. To amplify the p21
complete cDNA from the pcDNA3.1/GS, the PCR condi-
tions were 94°C/15 sec., 58°C/30 sec., and 72°C/60 sec.
for 35 cycles (slope = 9.9) in an air thermocycler (Idaho
Technology, Idaho Falls, Idaho). Each of five 10 µL PCR
reaction mixtures contained 2 mM dNTPs, 10×, 30 mM
MgCl2, template (pcDNA3.1/GSp21), forward and reverse
primers (0.1 µg/µL), Platinum Pfx DNA Polymerase (Inv-
itrogen, Inc., Carlsbad, CA), and RNase-free water. After
amplification, the five reactions were combined and elec-
trophoresed in a 2% (NuSieve/SeaKem) agarose gel con-
taining ethidium bromide. The PCR product was
visualized under UV and extracted following the Qiagen
gel extraction protocol (Qiagen, Santa Clarita, CA). The
TOPO reaction was performed according to manufac-
turer's instructions. The pENTR/D-TOPO-p21 vector was
isolated, quantified, and sequenced to confirm integrity
and orientation. Next, the Gateway™ (Invitrogen, Inc.,
Carlsbad, CA) LR site-specific recombination system was
used according to manufacturer's instructions to recom-
bine the p21 ORF from the entry vector (pENTR/D-
TOPO-p21) with the destination vector (pT-REx-
DEST30), which contains two tetracycline operon
(TetO2) sites within the human CMV promoter for tetra-
cycline-regulated expression of the inserted gene.
Stable transfection of cloned vectors
A549 cells were trypsin-dissociated, and each well of a 24-
well dish was inoculated with 105 cells (90–95% conflu-
ent on the day of transfection) in 500 µL of RPMI and
10% Tet-system approved FBS (Clontech, Palo Alto, CA)
without antibiotics. Twenty-four hours later, A549 cells
were transfected with the pcDNA/TR vector (Invitrogen,
Inc., Carlsbad, CA) that expresses the Tet-repressor. For
each well of cells transfected, 1 µg of vector DNA (pcDNA/
TR) was diluted into 50 µL of Opti-MEM I Reduced Serum
Medium (Gibco, Carlsbad, CA). Two microliters of Lipo-
fectamine 2000 (LF2000) (Invitrogen, Inc., Carlsbad, CA)
was diluted into 50 µL of Opti-MEM I Medium (Gibco,
Carlsbad, CA) and subsequent transfection was per-
formed according to LF2000 manufacturer's instructions.
At 24 hours post-transfection, the cells from each well
were trypsin-dissociated and inoculated into correspond-
ITAI values and bivariate analysis for A549, A549/p21 clone  1, 29, 30, and 32 Figure 5
ITAI values and bivariate analysis for A549, A549/p21 
clone 1, 29, 30, and 32. A) Mean TA value for each gene 
(from Figure 2) was used to calculate the ITAI. B) Bivariate 
analysis of p21 and [MYC × E2F1] for parental A549, A549/
p21 clones and samples in their vicinity that demonstrates 
the 2-fold increase in p21, the 5-fold decrease in E2F1, and 
subsequent ITAI value that is below the cut-off threshold.
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ing 10 cm plates containing fresh growth medium, RPMI
and 10% Tet-system approved FBS (Clontech, Palo Alto,
CA) without antibiotics. The next day, selective medium
was added containing blasticidin S-HCl (Invitrogen, Inc.,
Carlsbad, CA) at the A549 minimum 100% lethal dose
(LD100) of 7 µg/mL. Within one week, individual foci
developed, and each of these were individually dissoci-
ated, transferred to a single well in a 24-well dish and cul-
tured in selection medium. The pcDNA/TR-A549 clonal
populations were expanded and then sequentially trans-
fected with the pT-REx-DEST30-p21 response vector by
means described above but using the A549 minimal LD100
for Geneticin (G418 sulfate) (Invitrogen, Inc., Carlsbad,
CA) at 450 µg/mL as the selection antibiotic pressure. The
pcDNA/TR/p21-A549 transfectants were maintained
under dual blasticidin S-HCl and Geneticin selection.
Lowest basal and the highest tetracycline-induced p21 TA
level after addition of 1 µg/mL of doxycycline was
assessed in passage 4 cells from each clone, with passage
1 being the passage of the initial double antibiotic resist-
ant clones.
The initial screen for inducible exogenous p21 expression
was done on cells from passage 4 of the A549/p21 clones.
Proliferation kinetics for A549, and A549/p21 clone 1 Figure 6
Proliferation kinetics for A549, and A549/p21 clone 1. Thirty mm Petri dishes were inoculated with 2 × 105 cells from 
either parental A549, clone 1, 29, 30, or 32, then incubated for 0, 24, 48, 72, or 96 hours. At each time point, cells were 
counted (total cell counts) and assessed for viability. Shown here are proliferation rates for parental A549 and A549/p21 clone 
1 cell populations because while the growth rates are statistically significant between parental A549 and the A549/p21 clones, 
the proliferation rates among the clones were statistically insignificant. The experiment was repeated in triplicate and data 
reported as mean +/- standard deviation. The error bars are too small to visualize on this scale. The asterisk at 72 hrs indicates 
the time point when clonal populations were approximately 80% confluent and exhibited decreased viability.
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All mRNA, protein, flow cytometric, and growth kinetic
assessments were performed at passage 5 and compared
to parental A549 with an equivalent number of passages
post-transfection.
RNA extraction and reverse transcription
For cultured or primary cells, pelleted cells were dissolved
in TriReagent (Molecular Research Center Inc., Cincin-
nati, OH) and total RNA was extracted according to man-
ufacturer's instructions and previously reported methods
[47]. Then, approximately 1 µg of total RNA was reverse
transcribed using oligo-dT primer and M-MLV reverse
transcriptase (Invitrogen, Inc., Carlsbad, CA) as described
previously [48].
Quantitative standardized RT (StaRT)-PCR
StaRT-PCR was used for all TA measurements [2-4]. For TA
measurement of each gene, cDNA from a cell or tissue
sample of interest was mixed with the internal standard
(IS) for the gene within a standardized mixture of internal
standards (SMIS). The presence of SMIS in each reaction
enabled end-point quantification and controlled for all
known sources of variation in PCR amplification, includ-
ing inter-sample variation in the presence of gene-specific
inhibitors. After PCR, 1 µL of the PCR product was electro-
phoresed and quantified using an Agilent 2100 bioana-
lyzer according to manufacturer's recommended protocol
(Agilent Technologies, Palo Alto, CA), and then each gene
was quantified based on the ratio of the endogenous gene
Flow cytometric DNA analysis on A549, A549/p21 clone 1, 29, 30, and 32 Figure 7
Flow cytometric DNA analysis on A549, A549/p21 clone 1, 29, 30, and 32. A) Determination of DNA content and 
events or cell number for parental A549 and A549/p21 clones constitutively expressing p21 (B-E) were performed as 
described in Methods and [50].
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product (NT, native template) to its respective internal
standard (IS) within the SMIS [2-4,49]. Because the initial
concentration of IS added into the PCR reaction was
known and it amplified with the same kinetics as the NT,
the initial NT concentration could be determined through
a ratio with the IS. Second, the calculated number of target
gene NT molecules was divided by the calculated number
of β-actin NT molecules to control for loading differences.
Although β-actin was used as the reference gene for all
measurements, it was possible to recalculate the data rela-
tive to any other single gene or combination of genes that
was measured. Primers-(obtained from Gene Express, Inc;
GEI, Toledo, OH) for TA measurement in all cultured and
primary samples of each gene comprising the ITAI (MYC,
E2F1, and p21) and β-actin were described previously [2].
The p21 primers hybridize in the 3' untranslated region of
the p21 cDNA. Therefore, in order to measure the p21 TA
in A549 and the stable A549/p21 transfectants, another
set of p21 primers (not commercially available) were
designed to discern between exogenous expression of p21
(transcribed from the CMV-regulated p21 expression vec-
tor) and total p21 expression (endogenous plus exoge-
nous). To specifically measure exogenous p21 TA, the
reverse primer was anchored in the 3' Hexa-His-tag
sequence that flanks the p21 ORF (reverse NT sequence,
5'GTGATGGTGATGATGACCG3'  while the forward was
5'ACCCTTGTGCCTCGCTCAG3'). In order to measure
total p21 exogenous plus endogenous TA level, forward
and reverse primers 5'GCCTGCCCAAGCTCTACCT3' and
5'GAGAAGATCAGCCGGCGTT3', respectively, were
designed that hybridize in the coding region of p21 and
not the 3' Hexa-His-tag sequence. Previously reported
data for TA measurement of MYC, E2F1, and p21 in cul-
tured normal BEC, all malignant BEC except H146 (Addi-
tional File 1), and primary BEC were obtained using SMIS
prepared in this laboratory [2]. More recent data were
obtained using the same methods except SMIS used were
those commercially available for StaRT-PCR from Gene
Express, Inc. (Toledo, OH). The previously published data
then were converted to values based on the commercial
SMIS. The conversion factor for each gene between the
two SMIS was determined by evaluating a set of cDNA
samples with each SMIS.
Western blotting and antibodies
Parental A549 and A549/p21 cells were lysed by three
consecutive freeze-thaws in a 0.25 M Tris lysis buffer (Inv-
itrogen, Inc., Carlsbad, CA) and total protein concentra-
tion was determined colorimetrically by the
bicinchoninic acid (BCA) assay (Pierce, Inc., Rockford,
IL). Samples were solubilized in NuPAGE LDS Sample
buffer (Invitrogen, Inc., Carlsbad, CA) and 20 µg was
loaded on a denaturing 7% NuPAGE Tris-Acetate gel (Inv-
itrogen, Inc., Carlsbad, CA). Protein bands were trans-
ferred to Invitrolon PVDF membranes (Invitrogen, Inc.,
Carlsbad, CA) as described by the manufacturer. Then, the
membranes were blocked with 5% non-fat dry milk in 1×
TBST (blocking buffer) for 1 hr at room temperature. For
determination of exogenous p21 protein expression, blots
were incubated overnight with Anti-His Tag Mab (Nova-
gen, Madison, WI) (1:2000) recognizing the Hexa-Histi-
dine fusion tag of p21 transactivated from the expression
vector contained in the stable A549/p21 clones. Blots
were then washed with 1× TBST and incubated with the
secondary antibody, HRP-conjugated anti-mouse IgG
(Fisher, Pittsburgh, PA) (1:5000) for 1 hr at 37°C. Blots
were washed three times with 1× TBST and once with 1×
TBS. Detection was performed by the commercially avail-
able ECL detection system (Santa Cruz biotechnology,
Santa Cruz, CA). For determination of total p21 protein
expression (exogenous plus endogenous), blots were
incubated with Anti-Waf1 (Ab-1) Mab (Oncogene Sci-
ence, Cambridge, MA) (1:500). HRP-conjugated goat
anti-mouse IgG (Santa Cruz biotechnology, Santa Cruz,
CA) (1:2000) was used as the secondary antibody. Meth-
odology was the same as described above. The Hexa-His-
tidine tag that flanks the ORF of p21 was necessary for
determining expression of p21, both mRNA and protein,
that was exogenously synthesized. To date, there is no evi-
dence suggesting deleterious effects of Hexa-Histidine tags
on the function of p21. Further, because the relative
expression of His-tagged p21 was low in the A549/p21
clones, unexpected alterations in expression profiles and
phenotype are less likely.
Cell proliferation characteristics
Sub-cultures of the clonal populations were maintained
and periodically sub-cultured for determination of maxi-
mum number of passages at optimal confluency (50% or
5 × 106 cells/T75 flask). To calculate the number of popu-
lation doublings at each passage, the log2 of the number
of cells inoculated was subtracted from the log2 of the cell
count for the cells harvested. This information was used to
determine the number of population doublings for each
clone.
Cell doubling time was determined by counting cells from
trypsinized monolayers. Viability was assessed based on
trypan-blue (Sigma-Aldrich, Saint Louis, MO) exclusion.
30 mm Petri dishes containing 2 × 105 cells from either
parental A549, clone 1, 29, 30, or 32 were used for each
time point (0, 24, 48, 72, and 96 hrs). The stable clones
were maintained with RPMI and 10% FBS containing 450
µg/mL G418. In order to rule out potential effects of the
antibiotic on cell proliferation, the experiment was
repeated in antibiotic-free medium. Both experiments
were repeated in triplicate and the doubling time was cal-
culated by plotting the graph of cell count versus time
using the third degree polynomial.Molecular Cancer 2006, 5:1 http://www.molecular-cancer.com/content/5/1/1
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For further demonstration of growth characteristics of the
A549/p21 clonal populations, variable numbers of cells
(1 × 105, 5 × 105, and 1 × 106 cells) were inoculated per
T75 flask for determination of percent confluency at
which cells ceased dividing.
Flow cytometry and determination of DNA content
To determine DNA content and cell cycle phase, cells from
the parental A549 and clones 1, 29, 30, and 32  were har-
vested at 50% confluency. Next, 1 × 104 cells were pre-
pared for analysis by the propidium iodide, detergent, and
trypsin nuclei method as described by Vindelov, et al.,
1982 [50]. The cells were then evaluated for DNA content
and cell number on an EPICS Elite Flow Cytometer (Beck-
man-Coulter Corp., Miami, FL, USA). Values were auto-
matically calculated by Multicycle AV software (Phoenix
Flow Systems, Inc., San Diego, CA, USA). Aggregates were
excluded by pulse height versus pulse area.
Graphic and statistical analysis
Sensitivity and specificity were determined by 2 × 2 table
analysis, and numerical variable differences were deter-
mined by paired-sample T-tests (p-value less than 0.05
was considered statistically significant) using SPSS 11.5.1
for Windows (SPSS, Chicago, IL). Determination of mean
TA and cell number, standard deviation of TA and cell
number, cell doubling time, and creation of graphs were
accomplished using Excel 2000 (Microsoft Corp., Red-
mond, WA).
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